| Title |
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
|
|---|---|
| Published in |
Advances in Therapy, October 2016
|
| DOI | 10.1007/s12325-016-0431-5 |
| Pubmed ID | |
| Authors |
Hillel Cohen, Donna Beydoun, David Chien, Tracy Lessor, Dorothy McCabe, Michael Muenzberg, Robert Popovian, Jonathan Uy |
| Abstract |
The Biosimilars Forum conducted a survey through an independent organization from November 20, 2015 to January 4, 2016 in order to assess current levels of awareness, knowledge, and perceptions of biosimilars among US specialty physicians who already prescribe biologics. The survey was intended to provide a baseline level of knowledge about biosimilars and will be repeated in 2-3 years in order to monitor trends over time. A 19-question survey was created by the Biosimilars Forum and was administered by an independent third party. Responses were obtained from 1201 US physicians across specialties that are high prescribers of biologics, including dermatologists, gastroenterologists, hematologist-oncologists, medical oncologists, nephrologists, and rheumatologists. The results of this survey highlight a significant need for evidence-based education about biosimilars for physicians across specialties. Five major knowledge gaps were identified: defining biologics, biosimilars, and biosimilarity; understanding the approval process and the use of "totality of evidence" to evaluate biosimilars; understanding that the safety and immunogenicity of a biosimilar are comparable to the originator biologic; understanding the rationale for extrapolation of indications; and defining interchangeability and the related rules regarding pharmacy-level substitution. Biosimilars Forum. |
X Demographics
The data shown below were collected from the profiles of 58 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 15 | 26% |
| United Kingdom | 8 | 14% |
| Canada | 2 | 3% |
| India | 2 | 3% |
| Spain | 1 | 2% |
| Saudi Arabia | 1 | 2% |
| Colombia | 1 | 2% |
| Unknown | 28 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 51 | 88% |
| Practitioners (doctors, other healthcare professionals) | 3 | 5% |
| Science communicators (journalists, bloggers, editors) | 2 | 3% |
| Scientists | 2 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 132 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 22 | 17% |
| Student > Ph. D. Student | 18 | 14% |
| Student > Master | 18 | 14% |
| Researcher | 11 | 8% |
| Student > Bachelor | 10 | 8% |
| Other | 19 | 14% |
| Unknown | 34 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 33 | 25% |
| Medicine and Dentistry | 21 | 16% |
| Agricultural and Biological Sciences | 8 | 6% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Chemistry | 4 | 3% |
| Other | 19 | 14% |
| Unknown | 42 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 111. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2024.
All research outputs
#378,538
of 25,389,520 outputs
Outputs from Advances in Therapy
#35
of 2,647 outputs
Outputs of similar age
#7,279
of 318,489 outputs
Outputs of similar age from Advances in Therapy
#3
of 45 outputs
Altmetric has tracked 25,389,520 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,647 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,489 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.